Former President Joe Biden was diagnosed with an “aggressive form” of prostate cancer that has a five-year survival rate of between 30% and 40%. The former president’s prostate cancer is characterized ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...

PSMA-PET has an important role in the accurate staging of recurrent prostate cancer. Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease ...

Breast Cancer Now and Prostate Cancer Research have joined forces to fund up to £600,000 of new research to tackle the spread of both cancers to the bones, known as bone metastasis. Nearly all types ...

TTUHSC researcher Srinivas Nandana, Ph.D., (left) and co-investigator Manisha Tripathi, Ph.D., received a grant from the U.S. Department of Defense to investigate the role of TBX2 in establishing the ...

Weill Cornell Medicine received a $1.5 million grant from the U.S. Department of Defense Prostate Cancer Research Program to develop new approaches for predicting the spread of cancer cells to the ...

Patients with metastatic hormone-sensitive prostate cancer and baseline bone pain at diagnosis have worse overall survival compared to those without bone pain, a post hoc study found. Patients with ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.